customer news Arna Ionescu Stoll customer news Arna Ionescu Stoll

Forma Therapeutics selects the R&D Logic platform for corporate planning, portfolio planning, tracking, time collection and reporting.

November 2015 — Located in Watertown, MA, Forma Therapeutics has selected the R&D Logic FP&A solution to manage their R&D intensive company. Forma is passionate about discovering and developing medicines that will make a difference in cancer and other genetically-driven diseases.

Read More
customer news Arna Ionescu Stoll customer news Arna Ionescu Stoll

Viking Therapeutics selects the R&D Logic platform for corporate planning, portfolio planning, tracking, time collection and reporting.

October 2015 — Viking, located in San Diego, California has selected R&D Logic's software for planning, tracking, analysis and reporting. Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

Read More
customer news Arna Ionescu Stoll customer news Arna Ionescu Stoll

Just Biotherapeutics selects the R&D Logic solution for corporate planning and reporting.

May 2015 — Just, located in Seattle, Washington has selected R&D Logic's software for planning, tracking, analysis and reporting. Just is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. Just believes that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.

Read More
customer news Arna Ionescu Stoll customer news Arna Ionescu Stoll

Retrophin selects the R&D Logic time collection solution.

January 2015 — Retrophin, located in New York, Cambridge and San Diego has selected R&D Logic's software for collecting and reporting R&D project effort and FTEs. Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.

Read More